Stifel resumed coverage of Rhythm Pharmaceuticals (RYTM) with a Buy rating and $78 price target The firm has “high conviction” that the setmealontide Phase 3 hypothalamic obesity study will succeed and is comfortable here, even if the stock risk/reward is admittedly downside biased,” as it views hypothalamic obesity as a blockbuster opportunity, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Promising Clinical Milestones and Strong Financial Outlook Reinforce Buy Rating for Rhythm Pharmaceuticals
- Rhythm Pharmaceuticals price target raised to $70 from $69 at H.C. Wainwright
- Rhythm Pharmaceuticals Faces Financial Risks Due to Convertible Preferred Stock Prioritization
- Rhythm Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
- Rhythm Pharmaceuticals price target raised to $81 from $75 at Citizens JMP
Questions or Comments about the article? Write to editor@tipranks.com